更新版Elecsys Anti-TPO II检测甲状腺过氧化物酶抗体的分析性能与临床性能
该研究评估了以两种单克隆抗体替代多克隆抗体的Elecsys Anti-TPO II在Cobas e 601和e 801上的分析性能与临床性能,并与Elecsys Anti-TPO及三种其他免疫方法比较。结果显示其精密度高、半定量一致性改善,临床灵敏度和特异性良好,支持用于常规临床诊断自身免疫性甲状腺疾病。
要点
- Elecsys Anti-TPO II在测量值≤30 IU/mL时重复性、中间精密度和再现性标准差<1.6 IU/mL,>30 IU/mL时变异系数<7%。
- 与比较方法半定量一致性为94.0-97.7%,优于Elecsys Anti-TPO的88.5-90.8%。
- 以≥20 IU/mL为切点,参考人群特异性97.4%,HT临床灵敏度90.5%,疾病对照组特异性90.7%。
核心结论
- Elecsys Anti-TPO II具有稳健的分析性能与临床性能,支持其在常规临床实践中用于诊断自身免疫性甲状腺疾病。
研究设计与样本
- 在三个中心、5天内评估重复性、中间精密度和再现性,覆盖多个试剂批号和分析仪。
- 使用218份覆盖测量范围的血清样本与Elecsys Anti-TPO及三种其他免疫方法进行方法学比较。
- 临床切点源自85例确诊桥本甲状腺炎(HT)患者,参考区间来自230名健康甲状腺功能正常个体。
- 在608例确诊HT、Graves病、非自身免疫性甲状腺疾病或非甲状腺自身免疫病患者中评估临床性能。
主要发现
- 重复性、中间精密度和再现性的标准差在测量值≤30 IU/mL时<1.6 IU/mL,在>30 IU/mL时变异系数<7%。
- 与比较方法的半定量一致性为94.0-97.7%,而Elecsys Anti-TPO为88.5-90.8%。
- 参考范围队列的第95百分位<8 IU/mL。
- 以≥20 IU/mL为切点,参考队列特异性为97.4%。
- HT临床灵敏度为90.5%,疾病对照组临床特异性为90.7%。
关键数值与推荐
- 临床切点≥20 IU/mL时,参考人群特异性97.4%。
- HT临床灵敏度90.5%,疾病对照组临床特异性90.7%。
- 测量值≤30 IU/mL时重复性、中间精密度和再现性标准差<1.6 IU/mL;>30 IU/mL时变异系数<7%。
- 与比较方法半定量一致性94.0-97.7%,Elecsys Anti-TPO为88.5-90.8%。
- 参考范围队列第95百分位<8 IU/mL。
临床怎么用
- 可用于常规临床实践中辅助诊断自身免疫性甲状腺疾病。
- 以≥20 IU/mL作为临床切点解读结果。
- 半定量一致性优于原Elecsys Anti-TPO,可减少方法间差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Use of polyclonal antibodies (pAbs) in immunoassays has limitations related to inter-batch variation and supply chain stability which may affect assay reproducibility, scalability, and sustainability. The Elecsys® Anti-TPO II assay, where the pAb of the Elecsys Anti-TPO assay has been replaced with two monoclonal antibodies, aims to address these factors. We evaluated analytical and clinical performance for Elecsys Anti-TPO II using Cobas® e 601 and e 801 analyzers. METHODS: Repeatability, intermediate precision, and reproducibility were assessed over 5 days at three sites, within/between multiple reagent lots and analyzers. Method comparisons were performed against Elecsys Anti-TPO and three other immunoassays, using 218 serum samples covering the measuring range. The clinical cutoff was derived from 85 patients with confirmed Hashimoto thyroiditis (HT); reference intervals determined using samples from 230 healthy euthyroid individuals. Clinical performance was evaluated in 608 patients with confirmed HT, Graves disease, non-autoimmune thyroid diseases, or non-thyroid autoimmune diseases. RESULTS: Elecsys Anti-TPO II demonstrated high precision (standard deviations for repeatability, intermediate precision, and reproducibility <1.6 IU/mL for measurements ≤30 IU/mL; coefficients of variation <7 % for measurements >30 IU/mL) and improved semi-quantitative agreement (94.0-97.7 %) with comparator assays, vs. Elecsys Anti-TPO (88.5-90.8 %). The 95th percentile of the reference range cohort was <8 IU/mL; specificity in this cohort was 97.4 % (cutoff of ≥20 IU/mL). Clinical sensitivity for HT was 90.5 %; clinical specificity in disease control groups was 90.7 %. CONCLUSIONS: Elecsys Anti-TPO II offers robust analytical and clinical performance, supporting its utility in diagnosing auto-immune thyroid diseases in routine clinical practice.
引用
- Burman KD, Schmeltz LR, Momoyama Y, et al. Analytical and clinical performance of the updated Elecsys Anti-TPO II assay for the detection of antibodies against thyroid peroxidase to aid in the diagnosis of autoimmune thyroid diseases. Clin Chem Lab Med. 2026. PMID: 42259764. doi:10.1515/cclm-2026-0044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。